Reference: https://pubmed.ncbi.nlm.nih.gov/39940362/
A recent randomized, single-center, open-label study published in Nutrients on January 30, 2025, investigated the effects of resveratrol supplementation on oxidative stress markers in patients with head and neck cancer (HNC) undergoing home enteral nutrition (HEN). The study aimed to assess whether resveratrol could enhance antioxidant defenses and improve cellular health in this patient population.
The study enrolled 72 adult patients diagnosed with HNC, all of whom were receiving HEN. Participants were randomly assigned to either the intervention group or the control group. The intervention group received 400 mg of liposomal resveratrol daily for 12 weeks in addition to their standard HEN regimen, while the control group continued with HEN alone. Out of the initial cohort, 40 patients completed the 12-week intervention period.
To evaluate the impact of resveratrol supplementation, researchers measured various oxidative stress markers and body composition parameters at baseline and after 12 weeks. The oxidative stress markers assessed included total antioxidant capacity (TAC), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH). Body composition was analyzed using phase angle (PhA) measurements, which serve as an indicator of cellular health and integrity.
The results demonstrated significant increases in TAC and SOD activity in both the resveratrol and control groups, suggesting an overall enhancement in antioxidant defenses. Notably, GPx activity increased significantly only in the resveratrol group, indicating a potential specific effect of resveratrol on this particular antioxidant enzyme. Conversely, MDA levels, which are indicative of lipid peroxidation and oxidative stress, rose in both groups but were more pronounced in the resveratrol group. GSH levels did not exhibit significant changes in either group over the study period.
In terms of body composition, the phase angle (PhA) increased significantly in the resveratrol group, while no significant change was observed in the control group. An increase in PhA is often associated with improved cellular membrane integrity and overall cellular health, suggesting that resveratrol supplementation may confer benefits beyond oxidative stress modulation.
The observed rise in MDA levels within the resveratrol group may reflect the compound's dual antioxidant and pro-oxidant activities, a phenomenon documented in previous studies. While resveratrol is renowned for its antioxidant properties, under certain conditions, it can exhibit pro-oxidant effects, potentially leading to increased lipid peroxidation. This duality underscores the complexity of resveratrol's biological actions and suggests that its effects may vary depending on the physiological context.
In conclusion, resveratrol supplementation in patients with head and neck cancer receiving home enteral nutrition appears to enhance antioxidant defenses, as evidenced by increased GPx activity and improvements in TAC and SOD levels. The significant rise in phase angle further suggests potential benefits to cellular health. However, the concomitant increase in MDA levels highlights the necessity for a nuanced understanding of resveratrol's dualistic effects.
These findings support the potential of resveratrol as a complementary antioxidant intervention in clinical oncology, warranting further investigation to elucidate its therapeutic role in managing oxidative stress and promoting cellular health in cancer care.
